Does Aetna cover Mounjaro в 2026?
Mounjaro (generic: tirzepatide) is FDA-approved для type 2 diabetes. Coverage on diabetes drugs is standard across major commercial plans, gated by PA criteria.
Last verified 2026-06-01. Coverage changes — always confirm with your plan administrator.
1. Aetna coverage status for Mounjaro
Usually covered (with prior authorization). Most plans list this drug on their formulary, gated by PA criteria below.
2. Prior-authorization criteria
Aetna typically requires the prescriber к document:
- Documented type 2 diabetes diagnosis (ICD-10 E11)
- Recent A1C lab value (typically ≥7.0%)
- Trial + failure of metformin (or contraindication)
- Provider attestation of medical necessity
3. Step-therapy requirements
Before approving Mounjaro, Aetna typically requires trial + documented failure of:
- Metformin (first-line for type 2 diabetes per ADA guidelines)
4. Common reasons for denial
- A1C below plan threshold
- Inadequate metformin trial documentation
- Off-label use for weight loss (Mounjaro/Ozempic prescribed solely for weight loss)
5. If denied — how к appeal
If denied, request the written denial letter (legally required), then file а written appeal within the timeline stated. Include: physician letter of medical necessity, lab values, treatment history, and any peer-reviewed clinical evidence. If first appeal fails, escalate к external review through your state insurance commissioner.
Tip: request your physician's office submit а formal "letter of medical necessity" — these significantly improve appeal outcomes.
6. If uncovered — affordable alternatives
If Aetna denies coverage и appeal fails, cash-pay options exist:
- Manufacturer savings programs — Lilly LillyDirect direct-to-consumer pricing (verify eligibility on the manufacturer site)
- Compounded tirzepatide via licensed compounding pharmacies — typically $200-400/mo cash-pay
- See our Mounjaro provider list для current pricing across telehealth programs